Literature DB >> 10576668

Expression of MAGE-1 and -3 genes and gene products in human hepatocellular carcinoma.

K Kariyama1, T Higashi, Y Kobayashi, K Nouso, H Nakatsukasa, T Yamano, M Ishizaki, T Kaneyoshi, N Toshikuni, T Ohnishi, K Fujiwara, E Nakayama, L Terracciano, G C Spagnoli, T Tsuji.   

Abstract

MAGE gene family encodes peptides recognized by autologous cytotoxic T lymphocytes in a major histocompatibility complex (MHC) class-I restricted fashion. In the present study, we have performed reverse-transcription polymerase chain reaction (RT-PCR) for the genes, as well as immunohistochemical analysis and Western blotting of MAGE-1 and -3 proteins in 33 surgically resected hepatocellular carcinomas (HCCs). MAGE-1 and -3 mRNAs were constitutively expressed exclusively in 78 and 42% of HCCs respectively. On immunohistochemistry with monoclonal antibodies, 77B for MAGE-1 and 57B for MAGE-3, MAGE-1 and -3 proteins were recognized in cytoplasm of only six among 33 (18%) and two of 29 HCCs (7%) respectively. The distribution pattern was mostly focal in HCC nodules. By contrast, the Western blot analysis revealed that the MAGE-1 (46 kDa) and -3 proteins (48 kDa) were expressed in 80 and 60% of 15 HCCs examined respectively. The proteins of MAGE-1 and -3 were also expressed exclusively in HCCs regardless of the histological grading and clinical staging. Our results indicate that the detection of the genes by RT-PCR or the proteins by Western blotting is useful for differentiating early HCCs from non-cancerous lesions, and that the peptides derived from MAGE-1 and -3 proteins might be suitable targets for immunotherapy of human HCC.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10576668      PMCID: PMC2362936          DOI: 10.1038/sj.bjc.6690810

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  36 in total

1.  Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.

Authors:  F O Nestle; S Alijagic; M Gilliet; Y Sun; S Grabbe; R Dummer; G Burg; D Schadendorf
Journal:  Nat Med       Date:  1998-03       Impact factor: 53.440

2.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

Authors:  P van der Bruggen; C Traversari; P Chomez; C Lurquin; E De Plaen; B Van den Eynde; A Knuth; T Boon
Journal:  Science       Date:  1991-12-13       Impact factor: 47.728

3.  Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies.

Authors:  Y T Chen; E Stockert; Y Chen; P Garin-Chesa; W J Rettig; P van der Bruggen; T Boon; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-01       Impact factor: 11.205

4.  Structure, chromosomal localization, and expression of 12 genes of the MAGE family.

Authors:  E De Plaen; K Arden; C Traversari; J J Gaforio; J P Szikora; C De Smet; F Brasseur; P van der Bruggen; B Lethé; C Lurquin
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

5.  Identification of potential CTL epitopes of tumor-associated antigen MAGE-1 for five common HLA-A alleles.

Authors:  E Celis; J Fikes; P Wentworth; J Sidney; S Southwood; A Maewal; M F Del Guercio; A Sette; B Livingston
Journal:  Mol Immunol       Date:  1994-12       Impact factor: 4.407

6.  Expression of genes MAGE-1, -2, and -3 by human maxillary carcinoma cells.

Authors:  M Eura; K Chikamatsu; K Ogi; K Nakano; K Masuyama; T Ishikawa
Journal:  Anticancer Res       Date:  1995 Jan-Feb       Impact factor: 2.480

7.  Expression of mage genes by non-small-cell lung carcinomas.

Authors:  P Weynants; B Lethé; F Brasseur; M Marchand; T Boon
Journal:  Int J Cancer       Date:  1994-03-15       Impact factor: 7.396

8.  Perspectives for immunization of HLA-A1 patients carrying a malignant melanoma expressing gene MAGE-1.

Authors:  M Marchand; F Brasseur; P van der Bruggen; P Coulie; T Boon
Journal:  Dermatology       Date:  1993       Impact factor: 5.366

9.  Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601.

Authors:  P van der Bruggen; J P Szikora; P Boël; C Wildmann; M Somville; M Sensi; T Boon
Journal:  Eur J Immunol       Date:  1994-09       Impact factor: 5.532

10.  Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes.

Authors:  B Gaugler; B Van den Eynde; P van der Bruggen; P Romero; J J Gaforio; E De Plaen; B Lethé; F Brasseur; T Boon
Journal:  J Exp Med       Date:  1994-03-01       Impact factor: 14.307

View more
  9 in total

Review 1.  Hepatocellular carcinoma--cause, treatment and metastasis.

Authors:  Z Y Tang
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

2.  Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma.

Authors:  Kazumasa Hiroishi; Junichi Eguchi; Toshiyuki Baba; Tomoe Shimazaki; Shigeaki Ishii; Ayako Hiraide; Masashi Sakaki; Hiroyoshi Doi; Shojiro Uozumi; Risa Omori; Takuya Matsumura; Tatsuro Yanagawa; Takayoshi Ito; Michio Imawari
Journal:  J Gastroenterol       Date:  2009-11-20       Impact factor: 7.527

3.  MAGE-3 and MAGE-4 genes as possible markers for early detection of metastases in hepatitis C virus Egyptian patients complicated by hepatocellular carcinoma.

Authors:  Yousri M Hussein; Amal F Ghareib; Randa H Mohamed; Mohamed I Radwan; Wael H Elsawy
Journal:  Med Oncol       Date:  2011-03-31       Impact factor: 3.064

4.  Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library.

Authors:  P Chames; S E Hufton; P G Coulie; B Uchanska-Ziegler; H R Hoogenboom
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

5.  MAGE-4 gene m-RNA and TGF in blood as potential biochemical markers for HCC in HCV-infected patients.

Authors:  Yousri M Hussein; Fouad E Morad; Magda A Gameel; Wafaa A Emam; Wael H El Sawy; Shereen A El Tarhouny; Eman S Bayomy; Nermin Raafat
Journal:  Med Oncol       Date:  2012-06-01       Impact factor: 3.064

6.  The significance of MAGED4 expression in non-small cell lung cancer as analyzed by real-time fluorescence quantitative PCR.

Authors:  Qin-Yun Ma; Lie-Wen Pang; Zhi-Ming Chen; Yong-Jun Zhu; Gang Chen; Ji Chen
Journal:  Oncol Lett       Date:  2012-07-04       Impact factor: 2.967

7.  In vivo enhancement of the MAGE-specific cellular immune response by a recombinant MAGE1-MAGE3-TBHSP70 tumor vaccine.

Authors:  Wang Junwei; Zhan Xiumin; Ye Jing; Yang Shoujing; Li Zengshan
Journal:  Cancer Cell Int       Date:  2016-06-17       Impact factor: 5.722

8.  Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma.

Authors:  Fujimasa Tada; Masanori Abe; Masashi Hirooka; Yoshiou Ikeda; Yoichi Hiasa; Yoon Lee; Nam-Chul Jung; Woo-Bok Lee; Hyun-Soo Lee; Yong-Soo Bae; Morikazu Onji
Journal:  Int J Oncol       Date:  2012-09-11       Impact factor: 5.650

9.  Induction of HCA587-specific antitumor immunity with HCA587 protein formulated with CpG and ISCOM in mice.

Authors:  Juanjuan Chen; Lijie Zhang; Weigang Wen; Jiaqing Hao; Pumei Zeng; Xiaoping Qian; Yu Zhang; Yanhui Yin
Journal:  PLoS One       Date:  2012-10-11       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.